查看文章

Background RSV-associated acute respiratory infections (ARI), particularly lower respiratory tract diseases (LRTD), present a significant disease burden in older adults. Currently, there are no approved vaccines against RSV. We present results from an ongoing study designed to demonstrate the vaccine efficacy (VE) of the AS01 E-adjuvanted RSVPreF3 OA in adults≥ 60 YOA.

Zoom Image Fig. 1 Vaccine efficacy against first episodes of RSV-confirmed LRTD and RSV-confirmed ARI (modified exposed set) Zoom Image Fig. 2 Cumulative incidence curves for RSV-confirmed LRTD (A) and RSV-confirmed ARI (B) reported up to the efficacy data lock point (modifies exposed set)

Methods This ongoing, phase 3, observer-blind, placebo-controlled, multi-country study (NCT04886596) enrolled adults≥ 60 YOA from the northern and southern hemispheres. Participants were randomized (1: 1) to receive a single dose of …